Worth reading
72In focus
Scored from 3 of 5 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
830000
SharesWording
Definitive
How definitive the wording is.Details of issuance or disposal
Report on the exercise status of the 10th Series of Stock Acquisition Rights issued through a third-party allotment (with exercise price adjustment clause)
Who receives how much
830,000 new shares (number of shares delivered from 1 April to 30 April 2026)
EVO FUND (allottee of the 10th Series of Stock Acquisition Rights)
The lower thin line represents the existing number of shares to which these shares will be added.
Existing Shares and Increase
+8.10%Rate of increase
10,288,500 shares11,118,500Shares
Equivalent to 8.1% (830,000 shares ÷ 10,288,500 issued shares as of the end of the month preceding the subject month; not stated in the filing as a dilution rate)
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
Terms of the stock acquisition rights
Exercise price
Subject to exercise price adjustment provisions. The exercise prices during the period were ¥135, ¥131, ¥126, ¥121 and ¥117. The lower limit for adjustments is Not disclosed
Number of Stock Acquisition Rights
Total issued: 82,700; exercised from the beginning of the month: 8,300; unexercised as of the current date: 69,800
Basis for determining the amount to be paid
The exercise prices during the period were ¥135, ¥131, ¥126, ¥121 and ¥117. The closing prices, average share prices and discount or premium rates used as the calculation basis are Not disclosed
Most recent equity financing
Timing 13 February 2026 / Type Issuance of the 10th Series of Stock Acquisition Rights (with exercise price adjustment clause), with EVO FUND as the allottee / Amount Not disclosed
| Item | Details |
|---|---|
| Type of issuance or disposal | Report on the exercise status of the 10th Series of Stock Acquisition Rights issued through a third-party allotment (with exercise price adjustment clause) |
| Number of shares to be issued or disposed of | 830,000 new shares (number of shares delivered from 1 April to 30 April 2026) |
| Intended allottee | EVO FUND (allottee of the 10th Series of Stock Acquisition Rights) |
| Dilution Rate | Equivalent to 8.1% (830,000 shares ÷ 10,288,500 issued shares as of the end of the month preceding the subject month; not stated in the filing as a dilution rate) |
| Total number of issued shares | 10,288,500 shares → 11,118,500 shares |
| Basis for determining the amount to be paid | The exercise prices during the period were ¥135, ¥131, ¥126, ¥121 and ¥117. The closing prices, average share prices and discount or premium rates used as the calculation basis are Not disclosed |
| Exercise price | Subject to exercise price adjustment provisions. The exercise prices during the period were ¥135, ¥131, ¥126, ¥121 and ¥117. The lower limit for adjustments is Not disclosed |
| Number of Stock Acquisition Rights | Total issued: 82,700; exercised from the beginning of the month: 8,300; unexercised as of the current date: 69,800 |
| Most recent equity financing | Timing 13 February 2026 / Type Issuance of the 10th Series of Stock Acquisition Rights (with exercise price adjustment clause), with EVO FUND as the allottee / Amount Not disclosed |
Items this document does not state (19)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMajor shareholders after the offeringImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To report the substantial exercise of these Stock Acquisition Rights during the period from 1 April to 30 April 2026.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.